16 Atopic Dermatitis Clinical Trials in Iowa City, IA (2026)

Q: How do I join a clinical trial in Iowa City?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Iowa City research site will contact you.

Recruiting Atopic Dermatitis Studies in Iowa City

NCT05768139Recruiting

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with...

Iowa City, IAPHASE1880 participantsEli Lilly and Company

View Study Details

NCT05719558Recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

The main aims of this study are: * To check the safety of ASP1002 in people with certain solid tumors. * To check if the people can tolerate ASP1002. * To find a suitable dose of ASP1002. This study ...

Iowa City, IAPHASE1798 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT05046600Recruiting

Registry of Arthrex Hand and Wrist Products

A Multi-Center, Prospective Registry to Evaluate the Continued Safety and Effectiveness of Hand and Wrist Products...

Iowa City, IA650 participantsArthrex, Inc.

View Study Details

NCT05844982Recruiting

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following ...

Iowa City, IAPHASE3600 participantsJaeb Center for Health Research

View Study Details

NCT05584670Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants ag...

Iowa City, IAPHASE1542 participantsSanofi

View Study Details

NCT07293351Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma ...

Iowa City, IAPHASE1474 participantsBristol-Myers Squibb

View Study Details

NCT07225127Recruiting

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cance...

Iowa City, IA408 participantsUniversity of Washington

View Study Details

NCT07244809Recruiting

Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adversity

Adverse childhood experiences (ACEs) represent highly stressful events in the first 18 years of life that include abuse, neglect, and household and community-level dysfunction. Greater exposure to ACE...

Iowa City, IANA300 participantsUniversity of Iowa

View Study Details

NCT07206225Recruiting

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called ...

Iowa City, IAPHASE1294 participantsPfizer

View Study Details

NCT07322263Recruiting

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults who...

Iowa City, IAPHASE2174 participantsMichael A. O'Donnell

View Study Details

NCT06860152Recruiting

Cochlear Implant Speech in Noise Processing

The study will help us in understanding the neural mechanisms by which listeners with a cochlear implant detect speech in noisy environments....

Iowa City, IANA150 participantsCraig D. Workman, PhD

View Study Details

NCT07020117Recruiting

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advan...

Iowa City, IAPHASE1150 participantsAktis Oncology, Inc.

View Study Details

NCT07436793Recruiting

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometri...

Iowa City, IAPHASE2140 participantsNew Mexico Cancer Research Alliance

View Study Details

NCT06406777Recruiting

Chronic Lung Allograft Dysfunction MRI Study

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathop...

Iowa City, IAPHASE1100 participantsSean Fain

View Study Details

NCT05932680Recruiting

Limited-duration Teclistamab

This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria...

Iowa City, IAPHASE275 participantsAbramson Cancer Center at Penn Medicine

View Study Details

NCT06493370Recruiting

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

This is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC. Assess rates of pathologic down...

Iowa City, IAPHASE248 participantsUniversity of Kansas Medical Center

View Study Details

About Atopic Dermatitis Clinical Trials in Iowa City

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 16 atopic dermatitis clinical trials recruiting participants in Iowa City, IA. These studies are seeking a combined 5,783 participants. Research is being sponsored by Eli Lilly and Company, Astellas Pharma Global Development, Inc., Arthrex, Inc. and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Iowa City — FAQ

Are there atopic dermatitis clinical trials in Iowa City?

Yes, there are 16 atopic dermatitis clinical trials currently recruiting in Iowa City, IA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Iowa City?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Iowa City research site will contact you about next steps.

Are clinical trials in Iowa City free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Iowa City studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 16 active trials in Iowa City are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated October 18, 2026 from ClinicalTrials.gov